The state of the fight: 

Regeneron and Roche’s REGEN-COV became the first antibody drug to score U.S. FDA clearance for post-exposure prophylaxis of Covid-19.
  Six-month data on Pfizer/BioNTech’s vaccine showed continuing high efficacy against severe disease.
  Antibody levels induced by Sinovac’s vaccine dropped sharply six months after completion of a two-dose regimen, according to new data.   Approved or authorized vaccines

New, six-month Pfizer/BioNTech vaccine…

The state of the fight: 

Gavi inked a 550-million-dose supply deal with China’s CNBG and Sinovac.
  Bharat Biotech applied for WHO Emergency Use Listing of its inactivated vaccine.
  Cuba authorized BioFarmaCuba’s Abdala vaccine.


Approved or authorized vaccines

The U.S. FDA granted Priority Review to Pfizer/BioNTech’s Comirnaty vaccine in the companies’ bid for full licensure, the companies announced Friday.
While the press release noted a…

The University of Oxford announced Monday that its Jenner Institute has launched a Phase 1 trial in Britain of its HIVconsvX novel “mosaic” vaccine candidate that targets a broad range of HIV-1 variants.

The trial—which will test a single dose of the T cell-inducing candidate followed by a booster at four weeks in HIV-negative adults considered not to be at high risk of infection—is the first in a series of evaluations of HIVconsvX as a “vaccine strategy in both HIV-negative…

The state of the hunt:

J&J’s vaccine became the first single-dose Covid-19 jab to receive EUL from the World Health Organization.
  A growing list of countries—including at least one COVAX AMC participant—suspended their rollouts of AstraZeneca’s vaccine over safety concerns.
  Monoclonal antibodies from Lilly and a separate mAb from GSK and Vir substantially cut the risk of hospitalization or death in people with mild or moderate Covid-19 at high risk of progression…

The state of the hunt:

J&J’s single-dose vaccine scored unanimous endorsement from a U.S. FDA advisory committee, clearing the way for a likely EUA.
  The COVAX Facility made its first shipments, sending vaccine doses to Ghana and Ivory Coast.
  Moderna and Pfizer made progress toward clinical trials of modified, variant-specific vaccines.



Approved or authorized vaccines
Pfizer/BioNTech shot continues strong showing…

The IMPAACT4TB consortium announced Wednesday that it will roll out a new, patient-friendly preventive tuberculosis therapy in five high-burden countries, beginning in February.

Led by African NGO the Aurum Institute (with funding from Unitaid), the program will provide a fixed-dose combination of “3HP”—a short-course TB treatment combining rifapentine and isoniazid—to Ethiopia, Ghana, Kenya, Mozambique and Zimbabwe. An agreement between manufacturer Macleods, Unitaid and the Clinton…

The state of the hunt:

COVAX has inked a deal for up to 40 million doses of Pfizer/BioNTech’s vaccine.
  India launched its mass vaccination campaign against Covid-19.
  China and India are both giving away vaccine doses to their neighbors.



Approved or authorized vaccines
China’s Sinovac jab more effective using three-week interval: A silver lining has emerged to last week’s middling news from the Butantan Institute’s…

Newly formed generics giant Viatris announced Monday that the U.S. FDA has tentatively approved its 10mg pediatric dolutegravir antiviral tablets for oral suspension for treatment of HIV-1.

According to the press release, the tentative approval—granted under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)—permits the distribution in certain PEPFAR countries of generic products still under U.S. patent or exclusivity protection.

Pfizer’s Upjohn generics subsidiary…

The state of the hunt:

CEPI expanded its funding for Clover Biopharmaceuticals’ S-Trimer Covid-19 vaccine candidate to $328 million.
  Humanigen touted positive interim Phase 3 results for lenzilumab and announced a cooperative R&D deal with the U.S. government.
  Russia approved a domestic version of Fujifilm’s Avigan for coronavirus outpatients, dubbing the product “the first [f]avipiravir-based drug in the world approved for the treatment of COVID-19.”


Two different four-month treatment regimens for tuberculosis proved non-inferior to the standard six-month regimens for their trial populations, according to Phase 3 results presented separately at last week’s Union World Conference on Lung Health.

First, a 13-country, U.S. Centers for Disease Control and Prevention-led trial of over 2,500 participants with drug-susceptible TB found that an abbreviated regimen—which modified the standard treatment (a combination of isoniazid, rifampin…